Zero Candida Applies to List its Shares on the TSX Venture Exchange

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology company focused on development and commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor, is pleased to announce that it has filed its application to list the Company's common shares (the " Common Shares ") on the TSX Venture Exchange (the " TSXV "). The application is available under the Company's profile on SEDAR+.

ZERO_CANDIDA_Logo

Zero Candida (formerly 1319743 B .C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company ("ZC" and "Acquisition" respectively). In connection with the completion of the Acquisition, the Company changed its name to Zero Candida Technologies Inc. and split its share capital on a fifty-five thousand five hundred fifty five (55,555) common shares for one (1) common share basis, so that 36 common shares of the Company, without par value which were issued and outstanding immediately before completion of the Acquisition, were split into 2,000,000 common shares without par value. Pursuant to the terms of the Acquisition, the Company issued a total of 17,533,037 common shares (9.6165 common shares in the capital of the Company for each ordinary share in the capital of ZC) (the " Payment Shares "). Following completion of the Acquisition, ZC became a wholly-owned subsidiary of the Company. In addition, in connection with closing of the Acquisition, the Company issued 1,450,643 incentive stock options to employees of ZC (9.6165 incentive Options in exchange for each currently outstanding ZC Option). The terms of the exercise of the Options shall be consistent with the terms of the originally issued underlying ZC securities.

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company:

Eli Ben-Haroosh
Asher Holzer
Orit Berger
Christina Cameron

Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company:

Eli Ben-Haroosh, Chief Executive Officer
Sophya Galper-Komet , Chief Financial Officer and Corporate Secretary

Eli Ben Haroosh, Founder & CEO: "Our new technology that will be a game changer in the field of women's health in the world. The company is advancing in its research with the hope of involving hospitals and academic institutions around the world. Our company's vision is to complete a pre-clinical study by 6/2025 and submit it to the FDA. The company continues to develop a final prototype for human use and will complete it by Q1 2025."

"Zero Candida has a potential to become a technological leader and use its ground-breaking technology to expand boundaries of non-chemical candida treatment," added Mr. Ben Haroosh

The listing of the Common Shares on the TSXV remains subject to the review of the TSXV and is contingent on the satisfaction of all listing and regulatory requirements. There is no assurance that the TSXV will approve the listing application or that the Company will complete the listing on the TSXV as currently proposed.

Subject to the final TSXV approval, the Common Shares are expected to commence trading on or about November 25, 2024 .

About ZC

ZC is a private Israeli company that was formed to commercially exploit a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device when used overnight, demonstrated a 99.9999% Candidiasis elimination in the vagina within 3 nights.

ZC developed a first prototype of its device in May of 2022 and immediately commenced its first laboratory tests as a "proof of concept".  In September 2023 ZC completed its pre-clinical animal studies and subsequently developed a protype (1st series) and commenced its validation. ZC is currently in the process of developing the design of its device and continues pre-clinical animal studies. ZC expects to pursue "Fast Track" approval with the FDA as a Class II De Novo device.

In May 2024 , ZC received a report with respect to its pre-clinical safety study, that indicated no abnormal findings in gross-pathology and histopathology and identified no safety concerns with respect to ZC blue light illumination device.

On behalf of the Board of Directors
Eli Ben-Haroosh, CEO
For further information please contact
Mr. Eli Ban-Haroosh at eli@zero-candida.com ; 972—51-565-2355

NO SECURITIES REGULATORY AUTHORITY HAS EITHER APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS RELEASE. NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES , AND DOES NOT CONSTITUTE AN OFFER TO SELL OR SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES , THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED, OR ANY SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

FORWARD-LOOKING STATEMENTS

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-Looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, including statements relating to the issuance of securities and their characteristics described herein, approval of the Company's Listing application, or other similar expressions, all statements, other than statements of historical fact included herein including, without limitation, statements regarding the securities herein. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; the satisfaction of the conditions imposed by the TSXV on the Listing; operational risks associated with protection of intellectual property rights, product liability; regulatory risks; enforcement of judgments against foreign person; foreign currency exchange fluctuation; economic, political and military instability in Israel ;; and the additional risks identified in the Listing Application to be filed under its issuer profile on SEDAR+ or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-Looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

Logo: https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg

Cision View original content: https://www.prnewswire.com/news-releases/zero-candida-applies-to-list-its-shares-on-the-tsx-venture-exchange-302308281.html

SOURCE Zero Candida

Cision View original content: http://www.newswire.ca/en/releases/archive/November2024/18/c6786.html

News Provided by Canada Newswire via QuoteMedia

ZCT:CC
The Conversation (0)
Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

According to the report: u   p to 75% of women will have at least one vaginal yeast infection in their life

- A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, will reach over USD 2 billion by 2030, with a compound annual growth rate of 5.25% globally and 3.9% in North America and 4.2% in Europe .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Private Placement

Syntheia Announces Private Placement

Syntheia Corp. (CSE: SYAI) (Syntheia.ai) (the "Company"), is pleased to announce that it intends to complete a non-brokered private placement financing for gross proceeds of up to $500,000 through the issuance of up to 5,000,000 units (each, a "Unit") at a price of $0.10 per Unit (the "Offering").

Each Unit will be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.13 until the date that is two years from the closing of the Offering (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.13 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Spearmint Proposes Share Consolidation

Spearmint Proposes Share Consolidation

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") announces that it intends to complete a consolidation of its issued and outstanding common shares (the "Shares") on the basis of one new Share (a "Post-consolidated Share") for every ten currently outstanding Shares (the "Consolidation"). The Company also announces it intends to change its name and its trading symbol in connection with the proposed Consolidation.

Completion of the Consolidation, name change and symbol change are subject to approval by the Canadian Securities Exchange (the "CSE"). The effective date of the Consolidation, name change and symbol change will be announced in a subsequent news release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Signs Non-Binding LOI for Call Center Acquisition

Syntheia Signs Non-Binding LOI for Call Center Acquisition

Syntheia Corp. (CSE :SYAI) ("Syntheia" or the "Company") (Syntheia.ai), a leading provider of conversational AI solutions for inbound telephone call management, is pleased to announce that it has entered into a non-binding letter of intent dated May 6, 2025 (the "LOI"), to acquire Beyond The Call Inc. ("BTC"), an arm's length party, and certain of its assets, a call Center in Ontario (the "Proposed Transaction").

Traditional call centers are inefficient legacy businesses with high staff turnover (~ 70%) that have challenges maintaining consistent service quality, maintaining high call volumes, increasing cost of labour along with shortage of qualified labour.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Aether Global Announces Share Consolidation

Aether Global Announces Share Consolidation

(TheNewswire)

Aether Global Innovations Corp.

Vancouver, B.C. TheNewswire - May 16, 2025 Aether Global Innovations Corp. (CSE: AETH) (OTC: AETHF) (Frankfurt: 4XA) (WKN# A2N8RH), a leader in drone management and automation, announces that the Company intends to consolidate its common shares (the " Shares ") on a ten (10) for one (1) basis (the " Consolidation ").

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Skyscrapers with logos of Apple, Amazon, Microsoft; "Tech 5" text overlay.

Tech 5: Earnings Season Continues as Meta, Microsoft, Apple and Amazon Report

This week was packed with significant developments across the tech and finance sectors.

Mixed earnings reports from four of the Magnificent Seven revealed the impact tariffs could have on future operations, while Mastercard (NYSE:MA) and Visa (NYSE:V) announced new artificial intelligence (AI) payment initiatives.

Meanwhile, Google (NASDAQ:GOOGL) faced antitrust challenges in court as NVIDIA (NASDAQ:NVDA) navigated changing AI chip export regulations.

Keep reading...Show less

Latest Press Releases

Related News

×